Heart failure: an increased risk for patients with type 2 diabetes?

Linked to 5 million deaths per year worldwide, type 2 diabetes (T2D) is a complex and heterogeneous clinical syndrome, as it represents an increased risk of deterioration of the various organs of the affected patient (heart, kidney, nervous system…).

Indeed, researchers have shown that patients with type 2 diabetes are at greater risk of developing heart failure (HF). To prevent this from happening, the ICAN UHI is setting up a multidisciplinary and personalized approach to patient care, which takes into account the causal relationships of all cardiometabolic diseases (diabetes, obesity, cardiovascular diseases…).

In this context, the ICAN UHI is developing the MET-INF-T2D study, which aims to detect metabolic heart failure associated with type 2 diabetes at an early stage through the identification of imaging biomarkers. Find out the purpose of this research study below!

Heart failure: a high risk in type 2 diabetes

With more than 3.5 million French people affected, diabetes can be a silent disease diagnosed too late, at the onset of an acute episode that requires medical management of the patient.

In this case, diabetes has unfortunately already damaged other organs, resulting in an increased risk of developing other cardiometabolic diseases (cardiovascular accidents, heart failure, renal failure, peripheral neuropathies …).

Indeed, heart failure in patients with type 2 diabetes is associated with a significant risk of deterioration in quality of life, recurrent hospitalizations and death.

It is therefore essential to identify patients with type 2 diabetes and undiagnosed myocardial dysfunction who are at high risk of acute heart failure decompensation.

As a reminder, there are 4 warning signs to watch out for to diagnose the presence of heart failure and prevent its worsening:

  • Unusual shortness of breath,
  • Swollen feet and ankles (edema),
  • Rapid weight gain,
  • Excessive fatigue.

The MET-INF-T2D study: towards detection of metabolic heart failure associated with type 2 diabetes

How can cardiac metabolism be acutely affected by changes in blood glucose?

Indeed, the reduction of glucose levels in type 2 diabetes leads to major metabolic changes whose consequences for the heart are not known.

It is therefore essential today to set up a global and personalized management of patients, thanks to a sharing of knowledge between the different disciplines.

Led by Prof. Fabrizio Andreelli (Diabetologist APHP, Pitié-Salpêtrière, IHU ICAN), the MET-INF-T2D study aims to better predict the evolution of type 2 diabetes in order to develop new therapies and improve the management of patients.

The objective of this research project is to demonstrate that cardiac metabolic inflexibility is present in some patients with chronic hyperglycemia and revealed during the treatment of their diabetes by insulin therapy.

This project is supported by Entrepreneurs & Go as a sponsorship.